# Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

> **NCT01994590** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Dovitinib
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01994590
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-19
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-06-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor stopped supplying study drug
- **Last updated:** 2019-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01994590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01994590, "Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01994590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*